Search Results - "De Groot, J.R."

Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis by Neefs, J, van den Berg, N.W.E, Limpens, J, Berger, W.R, Boekholdt, S.M, Sanders, Prashanthan, de Groot, J.R

“…Abstract Background Despite advances in therapeutic interventions AF remains a progressive and symptomatic disease. Therefore, novel therapeutic interventions…”
Get full text

Combined leadless pacemaker and subcutaneous implantable defibrillator therapy: feasibility, safety, and performance by Tjong, F V Y, Brouwer, T F, Smeding, L, Kooiman, K M, de Groot, J R, Ligon, D, Sanghera, R, Schalij, M J, Wilde, A A M, Knops, R E

“…The subcutaneous implantable cardioverter-defibrillator (S-ICD) and leadless pacemaker (LP) are evolving technologies that do not require intracardiac leads…”
Get full text

Weighing the risks: Thrombotic and bleeding events in adults with atrial arrhythmias and congenital heart disease by Heidendael, J.F, Bokma, J.P, de Groot, J.R, Koolbergen, D.R, Mulder, B.J.M, Bouma, B.J

“…Abstract Introduction Atrial arrhythmias are associated to thromboembolism and anticoagulant treatment is installed according to risk profile. This study aimed…”
Get full text

Response to “comment on “aldosterone pathway blockade to prevent atrial fibrillation: A systematic review and meta-analysis” by Neefs et al.” by Neefs, J, van den Berg, N.W.E, Limpens, J, Berger, W.R, Boekholdt, S.M, Sanders, P, de Groot, J.R

Get full text

Postoperative arrhythmias in adults with congenital heart disease: Incidence and risk factors by Koyak, Z, Achterbergh, R.C.A, de Groot, J.R, Berger, F, Koolbergen, D.R, Bouma, B.J, Lagrand, W.K, Hazekamp, M.G, Blom, N.A, Mulder, B.J.M

“…Abstract Background Little is known about the clinical impact of arrhythmias after surgery for congenital heart disease (CHD) in adults. Therefore, we…”
Get full text

Myocardial infarction, atrial fibrillation and mortality: timing is everything by van den Berg, N.W.E., de Groot, J.R.

“…A subgroup analysis of nine studies that explicitly defined the new onset of AF showed similar results with an odds ratio (OR) of 1.37 (95 % confidence…”
Get full text

Rate and rhythm control treatment in the elderly and very elderly patients with atrial fibrillation: an observational cohort study of 1,497 patients by Klamer, T.A, Bots, S.H, Neefs, J, Tulevski, I.I, Somsen, G.A, Den Ruijter, H.M, De Groot, J.R

“…Abstract Aim Stroke prevention and rate or rhythm control are crucial parts of the treatment of atrial fibrillation (AF). There is limited evidence for the…”
Get full text

Low mortality rate after atrial fibrillation ablation: results from the Netherlands Heart Registration by Mol, D, Roefs, M.M, Blaauw, Y, De Jong, J.S.S.G, De Groot, J.R

“…Abstract Background Ablation therapy is widely used as a treatment of atrial fibrillation (AF) and is associated with 3.6% minor and major complications in the…”
Get full text

Age-adjusted risk factors are independently associated with an increased risk of ischaemic stroke, transient ischaemic stroke and systemic embolism in the ETNA-AF-Europe registry by De Caterina, R, De Groot, J.R, Weiss, T.W, Kelly, P, Monteiro, P, Deharo, J.C, De Asmundis, C, Lopez-De-Sa, E, Waltenberger, J, Steffel, J, Levy, P, Bakhai, A, Pecen, L, Kirchhof, P

“…Abstract Background Oral anticoagulation is highly effective in preventing ischaemic stroke in patients with atrial fibrillation, but 1–2% of the patients…”
Get full text

Signs of heart failure with preserved ejection fraction in atrial fibrillation patients normalise in many patients after restoration of sinus rhythm by Wagemakers, M.C.P, Wesselink, R, Neefs, J, Kougioumtzoglou, A, Van Den Berg, N.W.E, De Bruin-Bon, R.H.A.C.M, Piersma, F.R, De Jong, J.S.S.G, Van Boven, W.J.P, Driessen, A.H.G, Van Gelder, I.C, De Groot, J.R

“…Abstract Background Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) coexist in many patients. AF and HFpEF are closely…”
Get full text

Age-adjusted risk factors are independently associated with an increased risk of major bleeding during the two-year follow-up of the ETNA-AF-Europe registry by Kirchhof, P, De Groot, J.R, Weiss, T.W, Kelly, P, Monteiro, P, Deharo, J.C, De Asmundis, C, Lopez-De-Sa, E, Waltenberger, J, Steffel, J, Levy, P, Bakhai, A, Pecen, L, De Caterina, R

“…Abstract Background Non-vitamin K antagonist oral anticoagulants (NOACs) are a preferred treatment option over warfarin for anticoagulation in patients with…”
Get full text

P1719A systematic review of microRNAs in atrial fibrillation: from expression signatures to functional implications by Van Den Berg, N.W.E., Kawasaki, M., Neefs, J., Tijsen, A.J.M., De Groot, J.R.

Get full text

Atrial fibrillation up to 50 days after cardiac surgery should be considered postoperative atrial fibrillation by Van Den Berg, N.W.E, Neefs, J, Kawasaki, M, Jongejan, A, Nariswari, F, Wesselink, R, Van Putte, B.P, Van Boven, W.J, De Jong, J.S.S.G, Hulsman, E.L, Havenaar, H, Klaver, M.N, Driessen, A.H.G, Boersma, L.V, De Groot, J.R

“…Abstract Introduction Postoperative atrial fibrillation (POAF) occurs in up to 45% of patients following cardiothoracic surgery and is defined as any atrial…”
Get full text

P6419Resuscitation for out-of-hospital cardiac arrest in adults with congenital heart disease by Vehmeijer, J.T., Hulleman, M., Kuijpers, J.M., Blom, M.T., Koster, R.W., Mulder, B.J.M., Tan, H.L., De Groot, J.R.

Get full text

P3614Atrial arrhythmias are not associated with stroke in adults with congenital heart disease under current anticoagulation treatment by Yang, H., Kuijpers, J.M., De Groot, J.R., Konings, T.C., Van Dijk, A., Sieswerda, G.T.J., Post, M.C., Mulder, B.J.M., Bouma, B.J.

Get full text

Body Mass Index and Body Fat Distribution and New-Onset Atrial Fibrillation. Sub study of The European Prospective Investigation Into Cancer and Nutrition in Norfolk (EPIC-Norfolk) Study by Neefs, J., Boekholdt, S.M., Khaw, K.-T., Luben, R., Pfister, R., Wareham, N.J., Meulendijks, E.R., Sanders, P., de Groot, J.R.

Get full text

Body mass index and body fat distribution and new-onset atrial fibrillation: Substudy of the European Prospective Investigation into Cancer and Nutrition in Norfolk (EPIC-Norfolk) study by Neefs, J., Boekholdt, S.M., Khaw, K.-T., Luben, R., Pfister, R., Wareham, N.J., Meulendijks, E.R., Sanders, P., de Groot, J.R.

“…Obesity is a recognized risk factor for new-onset atrial fibrillation (AF). The association between body fat distribution, which is measured by body mass index…”
Get full text

P4597Health-related quality of life change after thoracoscopic surgery for advanced atrial fibrillation: results of the AFACT study by Berger, W.R., Driessen, A.H.G., Bierhuizen, M.F.A., Piersma, F.R., Van Den Berg, N.W.E., Neefs, J., Krul, S.P.J., Van Boven, W.J.P., De Groot, J.R.

Get full text

5719Edoxaban versus warfarin in patients with atrial fibrillation in relation to stroke risk. A subanalysis of the ENGAGE AF-TIMI 48 study by De Groot, J.R., Ruff, C.T., Murphy, S.A., Oude Ophuis, A.J.M., Grip, L., Antman, E., Lanz, H., Mercuri, M.F., Braunwald, E., Giugliano, R.P.

Get full text

P2650Left atrial linear ablation negatively affects atrial function by Van Den Berg, N.W.E., Chan Pin Yin, D.R.P.P., Neefs, J., De Bruin-Bon, H.A.C.M., Baalman, S.W., Berger, W.R., Driessen, A.H.G., Van Boven, W.J.P., De Groot, J.R.

Get full text